Based on the literature data, we selected 11 putative biomarkers for DLBCL: ASF1B, CD82B, CRISP3, FN1, MEF2B, PD-L1, TIMP1, TOP2A, and TP53. This evidence concerns the gene TP53 and diffuse large B-cell lymphoma.